|Bid||6.42 x 100|
|Ask||7.21 x 400|
|Day's range||6.65 - 6.86|
|52-week range||4.31 - 12.49|
|PE ratio (TTM)||N/A|
|Earnings date||7 May 2018 - 11 May 2018|
|Forward dividend & yield||N/A (N/A)|
|1y target est||8.57|
President Donald Trump said he's considering suing drugmakers for their role in fueling the opioid epidemic, sending pharma stocks tumbling.
Collegium touched a buy zone Thursday after sales of painkiller Xtampza easily beat Street expectations in the fourth quarter.
In fiscal 2017, Depomed (DEPO) generated total revenues of $380.7 million. Of these total revenues, $379.8 million came from product sales, and ~$844,000 came from royalties. By comparison, the company had generated total revenues of $455.8 million in fiscal 2016, of which $455 million came from product sales and $831 million from royalties.
Depomed (DEPO) has adopted a three-pronged business strategy with three key elements: maintain, build, and grow. Depomed aims to maintain its Nucynta franchise of pain products through the commercialization agreement it entered into with Collegium Pharmaceutical in December 2017. Under this agreement, Depomed granted commercialization rights for the Nucynta franchise of pain products to Collegium Pharmaceutical in the US.
Depomed (DEPO) generates a major part of its sales from five major products: Nucynta, Gralise, Cambia, Lazanda, and Zipsor. Sales of products in Depomed’s Nucynta franchise fell from $281.2 million in fiscal 2016 to $239.5 million in fiscal 2017. Depomed acquired the Nucynta franchise from Janssen in April 2015.
Depomed (DEPO) is a specialty pharmaceutical company with a focus on pain and CNS (central nervous system) conditions. In March 2018, two of the seven analysts covering Depomed have given the stock a “buy” rating. By comparison, of the 22 analysts covering Merck (MRK) in March 2018, six analysts have given the stock a “strong buy” rating, and seven analysts have given it a “buy” rating, while nine analysts have given it a “hold” rating.
On a per-share basis, the Newark, California-based company said it had a loss of 52 cents. Earnings, adjusted for non-recurring costs and pretax expenses, were 15 cents per share. The results beat Wall ...
Collegium rocketed to a 22-month high Tuesday after striking a deal with Depomed to commercialize its painkiller Nucynta.
Shareholder rights law firm Robbins Arroyo LLP announces that a class action complaint was filed against Depomed, Inc. . The complaint is brought on behalf of all purchasers of Depomed securities between February 26, 2015 and August 7, 2017, for alleged violations of the Securities Exchange Act of 1934 by Depomed's officers and directors.
Glancy Prongay & Murray LLP reminds investors of the October 17, 2017 deadline to file a lead plaintiff motion in the class action filed on behalf of investors that purchased Depomed, Inc.
Law Offices of Howard G. Smith reminds investors of the October 17, 2017 deadline to file a lead plaintiff motion in the class action filed on behalf of investors that purchased Depomed, Inc.
Scott+Scott, Attorneys at Law, LLP , a national shareholder and consumer rights litigation firm, reminds investors that October 17, 2017, is the deadline to move for lead plaintiff status in the securities class action pending against Depomed, Inc.